Thierry Andre

Summary

Country: France

Publications

  1. ncbi request reprint An overview of adjuvant systemic chemotherapy for colon cancer
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Clin Colorectal Cancer 4:S22-8. 2004
  2. ncbi request reprint [Adenocarcinoma of the pancreas. General characteristics]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    Presse Med 27:533-6. 1998
  3. ncbi request reprint Cancer of the pancreas
    Thierry Andre
    Service d Oncologie, Hopital Tenon, APHP et Cancer Est, Paris
    Gastroenterol Clin Biol 30:2S75-2S80. 2006
  4. ncbi request reprint [Colon cancer: what is new in 2004?]
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Bull Cancer 91:75-80. 2004
  5. ncbi request reprint Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2)
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris
    Gastroenterol Clin Biol 28:645-50. 2004
  6. ncbi request reprint Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial
    Thierry Andre
    Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
    J Clin Oncol 21:2896-903. 2003
  7. ncbi request reprint Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
    T Andre
    Oncology Department, Tenon Hospital, Paris, France
    Ann Oncol 15:1339-43. 2004
  8. ncbi request reprint Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study
    T Andre
    Department of Medical Oncology, University Hospital, Grenoble, France
    Int J Radiat Oncol Biol Phys 46:903-11. 2000
  9. ncbi request reprint [Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    J Chir (Paris) 136:309-17. 1999
  10. ncbi request reprint Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
    T Andre
    Hopital Tenon, Clinique du Mont Louis, Paris, France
    J Clin Oncol 17:3560-8. 1999

Detail Information

Publications60

  1. ncbi request reprint An overview of adjuvant systemic chemotherapy for colon cancer
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Clin Colorectal Cancer 4:S22-8. 2004
    ..Future studies in adjuvant therapy for colon cancer will explore oxaliplatin and 5-FU with or without antiangiogenesis or anti-epidermal growth factor agents...
  2. ncbi request reprint [Adenocarcinoma of the pancreas. General characteristics]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    Presse Med 27:533-6. 1998
    ..Few risk factors have been identified. Smoking increases the relative risk by 1.5, chronic pancreatitis by 26. Hereditary formes are rare...
  3. ncbi request reprint Cancer of the pancreas
    Thierry Andre
    Service d Oncologie, Hopital Tenon, APHP et Cancer Est, Paris
    Gastroenterol Clin Biol 30:2S75-2S80. 2006
  4. ncbi request reprint [Colon cancer: what is new in 2004?]
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Bull Cancer 91:75-80. 2004
    ..Shrinkage of tumours after administration of preoperative chemotherapy and availability of ablative techniques (radiofrequency and cryotherapy) now allow to treat with curative intent metastases initially considered as non-resectable...
  5. ncbi request reprint Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2)
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris
    Gastroenterol Clin Biol 28:645-50. 2004
    ..The aims of this phase II multicentric study were to evaluate the response rate, clinical benefit and tolerance of a new scheme of combined leucovorin, 5-FU and gemcitabine (FOLFUGEM 2)...
  6. ncbi request reprint Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial
    Thierry Andre
    Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
    J Clin Oncol 21:2896-903. 2003
    ....
  7. ncbi request reprint Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
    T Andre
    Oncology Department, Tenon Hospital, Paris, France
    Ann Oncol 15:1339-43. 2004
    ..Since gemcitabine-oxaliplatin (GEMOX) has been used in pancreatic adenocarcinoma, we studied its activity and tolerability in advanced biliary tract adenocarcinoma (ABTA)...
  8. ncbi request reprint Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study
    T Andre
    Department of Medical Oncology, University Hospital, Grenoble, France
    Int J Radiat Oncol Biol Phys 46:903-11. 2000
    ..The quality of palliation and percentage of secondary resections were also studied for unresectable disease...
  9. ncbi request reprint [Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    J Chir (Paris) 136:309-17. 1999
    ..There is an urgent need for more effective treatments against metastatic disease and for better loco-regional management using a multidisciplinary approach. These patients should be treated within the framework of therapeutic trials...
  10. ncbi request reprint Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
    T Andre
    Hopital Tenon, Clinique du Mont Louis, Paris, France
    J Clin Oncol 17:3560-8. 1999
    ....
  11. ncbi request reprint [Adenocarcinoma of the pancreas. Therapeutic strategies]
    T Andre
    Service d Oncologie Medicale, Hopital Tenon, Paris
    Presse Med 27:539-45. 1998
    ..After complete resection 70 to 80% of patients develop a local recurrence. Biliary and gastro-intestinal bypasses as well as antalgic techniques are useful palliative procedures...
  12. doi request reprint Platinum-sensitivity in metastatic colorectal cancer: towards a definition
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, APHP, Paris, France Université Pierre et Marie Curie, Universite Paris 6, Paris, France GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris, France Electronic address
    Eur J Cancer 49:3813-20. 2013
    ..Influence of the first-line oxaliplatin-based treatment efficacy and the duration of OFI on tumour sensitivity to oxaliplatin reintroduction were investigated...
  13. ncbi request reprint [Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ]
    Joseph Gligorov
    Service d Oncologie Medicale, Hopital Tenon, 4, rue de la Chine, 75020 Paris
    Bull Cancer 89:S134-44. 2002
    ..The growing interest in gemcitabine-based combinations in various tumor types together with the results presented at ASCO 2002 confirm the broad range of activity of this drug. This is a review of papers presented at ASCO 2002...
  14. ncbi request reprint Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    May Mabro
    Department of Medical Oncology, Hopital Saint Antoine, Paris, France
    Am J Clin Oncol 26:254-8. 2003
    ..FOLFIRI-2 achieved a good rate of response and stabilization in heavily pretreated patients despite significant toxicity...
  15. ncbi request reprint Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1
    Thierry Andre
    Public Hôpitaux de Paris and CancerEst, Hopital Tenon, Paris, France
    J Clin Oncol 25:3732-8. 2007
    ....
  16. ncbi request reprint Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
    ..These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers...
  17. ncbi request reprint OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 24:394-400. 2006
    ..This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin...
  18. doi request reprint Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Tre
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 30:3353-60. 2012
    ..Oxaliplatin combined with fluoropyrimidine improves survival in patients with stage III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II and elderly patients...
  19. ncbi request reprint Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Thierry Andre
    Hopital Tenon, Paris
    N Engl J Med 350:2343-51. 2004
    ..Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting...
  20. doi request reprint Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study
    Mohamed Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    J Chemother 25:104-11. 2013
    ..To evaluate the MIROX strategy (6 FOLFOX7 cycles followed by 6 FOLFIRI cycles) in patients with resected or resectable metastases from colorectal cancer...
  21. doi request reprint Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
    Laurence Moureau-Zabotto
    Hopital Tenon, Service de Radiotherapie, 4 rue de la Chine, 75020 Paris, France
    J Clin Oncol 26:1080-5. 2008
    ....
  22. pmc Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
    ..The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer...
  23. ncbi request reprint [Gemcitabine and digestive carcinomas]
    Pierre Blanchard
    service d oncologie radiothérapie, Hopital Tenon, Paris
    Bull Cancer 94:S104-15. 2007
    ..The aim of this review is to describe the trials that have contributed to determine gemcitabine's infusion modalities in pancreatic cancer. We will then present the studies that have been carried out in other digestive cancers...
  24. ncbi request reprint Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)
    Christophe Louvet
    Service de médecine interne oncologie, Hopital St Antoine, 184 rue du fbg St Antonie, 75012, Paris, France
    Cancer Invest 21:14-20. 2003
    ..Response rate and survival in patients with gastric linitis or diffuse forms were in the same range as in patients with intestinal forms of gastric adenocarcinoma...
  25. doi request reprint Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
    Isabelle Baumgaertner
    Department of Hepatogastroenterology, Hopital Pitie Salpetriere, Paris, France
    Clin Colorectal Cancer 9:E5-10. 2010
    ..These analyses compare the safety and efficacy of 2 forms (levogyre [L] and dextro-levogyre [DL]) of leucovorin (LV) when used with 5-fluorouracil (5-FU) for the adjuvant treatment of patients with stage II and III colon cancer...
  26. doi request reprint From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
    ..Clarity regarding the clinical signal needed before launching a phase III study and optimized designs adapted to multiple agents are urgently needed for new trials...
  27. doi request reprint [Cutaneous adverse reactions of EGFR (epidermal growth factor receptor)-inhibitors: therapeutic algorithm of the French PROCUR group]
    Claude Bachmeyer
    Assistance Publique Hopitaux de Paris, Hopital Tenon, Service de Medecine Interne, 4, rue de la Chine, 75020 Paris, France
    Bull Cancer 100:417-26. 2013
    ..This multidisciplinary study should facilitate the standardised, optimised management of skin toxicity associated with EGFR-inhibitors...
  28. doi request reprint [Anticancer chemotherapy in the elderly: a review of the literature]
    Isabelle Debrix
    Service de Pharmacie, Hopital Tenon, Cancer Est 4, rue de la Chine, 75020 Paris, France
    Bull Cancer 95:F37-43. 2008
    ..Rather than the criteria of age, comorbidities should be considered. It is necessary to develop specific geriatric assessment and development of clinical trials specifically including elderly patients remains a necessity...
  29. doi request reprint The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
    ..The synthesis of these data allows us to conceive a future development focused on translational research...
  30. ncbi request reprint [Anti-angiogenic treatment and colorectal cancer]
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4, rue de la Chine, 75970 Paris Cedex 20
    Bull Cancer 94:S211-9. 2007
    ..Several questions regarding the optimal use of bevacizumab still remain to be answered in the treatment of metastastic colorectal cancer. Vatalanib has not shown benefit in this pathology...
  31. ncbi request reprint Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
    Florence Huguet
    Department of Radiation Oncology, Tenon Hospital, Assistance Publique Hopitaux de Paris, France
    J Clin Oncol 25:326-31. 2007
    ..The decision to administer CRT or continue CT in nonprogressive patients was the investigator's choice...
  32. ncbi request reprint Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
    Frédérique Maindrault-Goebel
    Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France
    Eur J Cancer 41:2262-7. 2005
    ..For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence...
  33. doi request reprint [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]
    Thierry Andre
    Hopital Saint Antoine, Service d Oncologie Medicale, 184, rue du Faubourg Saint Antoine, 75012 Paris, France
    Bull Cancer 100:1023-5. 2013
    ..Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA and a EMEA approval for patients with metastatic colorectal cancer...
  34. doi request reprint S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
    Jean Baptiste Bachet
    Medical University Pierre et Marie Curie, UFR Paris VI, 91 105 boulevard de l Hôpital, Paris, France
    Eur J Cancer 49:2643-53. 2013
    ..S100A2 has been recently suggested as a negative prognostic biomarker in PAC. We aimed to investigate its prognostic and/or predictive value in a large independent multicentric cohort of patients with resected PAC...
  35. doi request reprint Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Lancet Oncol 13:1225-33. 2012
    ..Our aim was to assess the use of bevacizumab in combination with oxaliplatin-based chemotherapy in the adjuvant treatment of patients with resected stage III or high-risk stage II colon carcinoma...
  36. doi request reprint Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions
    Benoist Chibaudel
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 9:269-73. 2010
    ..A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials...
  37. ncbi request reprint Stage II and stage III colon cancer: treatment advances and future directions
    Benoit Rousseau
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
    Cancer J 16:202-9. 2010
    ..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials...
  38. pmc Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set
    Aimery de Gramont
    Hopital Saint Antoine, Group Hospitalier Pitie Salpetriere, Paris, France
    J Clin Oncol 28:460-5. 2010
    ..New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association...
  39. ncbi request reprint Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment
    Suzanne Nguyen
    Service d Oncologie, Centre Hospitalier, 40 avenue Léon Blum, 60021 Beauvais Cedex, France
    Bull Cancer 93:E1-6. 2006
    ..We report here the results of these two phase II studies...
  40. ncbi request reprint [Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma in 2006]
    Mélanie Deberne
    service d oncologie radiothérapie, Hopital Tenon, Paris
    Bull Cancer 94:72-80. 2007
    ..This is under evaluation. This paper presents a summary of adjuvant and neoadjuvant trials for patients with potentially resectable pancreatic adenocarcinoma...
  41. pmc Current status of adjuvant therapy for colon cancer
    Thierry Andre
    Hopital Tenon, Paris, France
    Gastrointest Cancer Res 1:90-7. 2007
    ..Duration of therapy and prevention of oxaliplatin neurotoxicity are other critical areas for future research...
  42. ncbi request reprint Targeted agents for adjuvant therapy of colon cancer
    Aimery de Gramont
    GERCOR Groupe Coopérateur Multidisciplinaire en Oncologie and Hôpital Saint Antoine, Paris, France
    Semin Oncol 33:S42-5. 2006
    ..Cetuximab is being evaluated in combination with FOLFOX4 and FOLFOX6 in the North Central Cancer Treatment Group (NCCTG) N0147 trial and the Pan European Trials in Adjuvant Colon Cancer (PETTAC) 8 trial...
  43. doi request reprint [Regorafenib approved in Metastatic Colorectal cancer]
    Thierry Andre
    Hopital Saint Antoine, Service d Oncologie Medicale, 184, rue du Faubourg Saint Antoine, Paris 75012, France Université Pierre et Marie Curie UPMC, Paris, France
    Bull Cancer 100:1027-9. 2013
    ..4 months vs 4 months; HR = 0.774, IC à 95%, 0.64 à 0.94; p = 0,005 2). Reported grade 3-4 adverse events with regorafenib were hand-foot syndrome (17%), asthenia (10%), diarrhea (7%), hypertension (7%), rash and desquamation (6%)...
  44. ncbi request reprint Current issues in adjuvant treatment of stage II colon cancer
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4 rue de la Chine, 75970, Paris Cedex 20, France, and Vall d Hebron University Hospital, Barcelona, Spain
    Ann Surg Oncol 13:887-98. 2006
    ..In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial...
  45. ncbi request reprint [PET and digestive cancers]
    Jean Noel Talbot
    Service de Medecine Nucleaire, AP HP, Hopital Tenon, F 75020 Paris, France
    Presse Med 37:e1-e24. 2008
    ....
  46. pmc Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review
    Jean Baptiste Bachet
    Department of Hepato gastro enterology, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Universite Pierre and Marie Curie, Paris, France
    Oncologist 17:555-68. 2012
    ..Variations in terms of the treatment-related incidence and intensity have not been fully elucidated. Tetracyclines have been recommended for the prophylaxis and treatment of folliculitis but their efficacy is yet to be established...
  47. ncbi request reprint [Gemcitabine-based combinations in inoperable pancreatic cancers]
    Christophe Louvet
    Service d Oncologie, Medecine Interne, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris
    Bull Cancer 89:S96-101. 2002
    ..We summarize the results of studies combining gemcitabine with 5FU, docetaxel, platinum-compounds, irinotecan and epirubicin. Some combinations seem to achieve an interesting efficacy, and are now compared to gemcitabine alone...
  48. ncbi request reprint [Anticancer drugs use evaluation: limits of the approved labeling]
    Isabelle Debrix
    Pharmacie, Hopital Tenon, 4, rue de la Chine, 75020 Paris
    Bull Cancer 91:437-43. 2004
    ..So, label used can not be the own references for anticancer drugs prescribing, therapeutic advanced can be realised and disseminated before their taking into account in the label used...
  49. ncbi request reprint Adjuvant therapy for stage II and III colorectal cancer
    Aimery de Gramont
    Groupe Coopérateur Multidisciplinaire en Oncologie, Hopital Saint Antoine, Service de médecine interne oncologie, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Semin Oncol 34:S37-40. 2007
    ..Studies are ongoing to identify optimal adjuvant regimens in stage II or III disease and to identify the potential benefits of adding bevacizumab or cetuximab to adjuvant therapy...
  50. ncbi request reprint FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
    ..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)...
  51. ncbi request reprint Cetuximab-induced acne
    Emmanuel Molinari
    Service de Dermatologie, Hopital Tenon, Paris, France
    Dermatology 211:330-3. 2005
    ..These molecules may induce acneiform eruptions. In this study, we aimed at evaluating (a) the characteristics of acne and (b) whether these acneiform eruptions could be improved by classical anti-acne treatments...
  52. pmc Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
    Thanh Khoa Huynh
    Service d Oncologie Medicale, CHU Timone, AP HM, Marseille, and Aix Marseille Universite, Marseille, France
    BMC Cancer 14:156. 2014
    ..Rectal and pararectal gastrointestinal stromal tumors (GISTs) are rare. The optimal management strategy for primary localized GISTs remains poorly defined...
  53. doi request reprint Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    Clin Cancer Res 19:1902-12. 2013
    ..To investigate whether EGF receptor (EGFR) pathway mutations predicted response to monotherapy with panitumumab, an anti-EGFR monoclonal antibody, in a randomized phase III study of metastatic colorectal cancer...
  54. doi request reprint [American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view]
    Stephane Vignot
    Groupe Hospitalier Pitie Salpetriere, Service d Oncologie Medicale, Paris Cedex, France
    Bull Cancer 98:1509-23. 2011
    ....
  55. doi request reprint EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    Virginie Poindessous
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    Clin Cancer Res 17:6522-30. 2011
    ..We speculated that inhibition of surface receptors and ligands might only partly prevent oncogenic signaling whereas small-molecule tyrosine kinase inhibitors (TKI) would also influence intracellular signaling...
  56. ncbi request reprint [Anticancer drugs off label used of: what do the experts think about?]
    Isabelle Debrix
    Pharmacie, Hopital Tenon, Paris
    Bull Cancer 91:769-77. 2004
    ..This method proposed by the local drug committee could be used to regulate economic resources and to justify financing of some expensive anticancer drugs...
  57. ncbi request reprint Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administratio
    Jean Marc Tourani
    Service d Oncologie Médicale and Unité de Biostatistique, Fédération de Cancérologie et d Hématologie, hôpital J Bernard, Poitiers, France
    J Clin Oncol 21:3987-94. 2003
    ....
  58. ncbi request reprint Colon cancer
    Philippe Rougier
    Service d Hepato Gastroenterologie, Hopital Ambroise Pare, Boulogne
    Gastroenterol Clin Biol 30:2S24-2S29. 2006
  59. ncbi request reprint Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
    Richard M Goldberg
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:4085-91. 2006
    ..This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than and at least 70 years...
  60. ncbi request reprint Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...